In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor ...

Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an ...

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may protect the kidneys better than glucagon-like peptide 1 receptor ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

On Thursday, members of the Endocrinologic and Metabolic Drugs Advisory Committee will help the FDA decide whether the ...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity.

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

A recent case report highlights the importance of understanding the possibility of the development of Euglycemic diabetic ...

Patients with broad range of kidney function show reduced effects following discontinuation after EMPA-KIDNEY trial.